Latest Little Green Pharma (ASX:LGP) News

Big moves came from point-of-care testing and a sharp sell-off in two names despite upbeat news. Meanwhile, several smaller caps pushed trials and regulatory files forward, giving investors clear dates to watch.

Little Green Pharma has issued a supplementary scheme booklet updating Cannatrek shareholders on the acquisition progress, including a revised timetable and the termination of a planned sale and leaseback of its WA production facility. Both companies’ boards continue to recommend the scheme, supported by an independent expert’s positive assessment.

A handful of small caps did the heavy lifting this week, led by a lung cancer trial green light and a steep sell-off after a capital raise. Investors paid up for clear clinical steps, but punished dilution and stocks that reopened lower and kept sliding.

Little Green Pharma has terminated its planned sale and leaseback of its Western Australian production facility after failing to reach commercial terms, choosing to retain ownership without impacting operations.

One stock nearly doubled, another jumped more than 40%, and a finance heavyweight stayed elevated after a merger shock. In resources, the winners were mostly tied to “what was bought” or “what was funded”, while the laggards were often the ones where early optimism quickly turned into selling.

Avecho and Chimeric both surged as traders chased near-term trial and funding catalysts, while Island Pharmaceuticals extended gains on a US biodefence partnership. Elsewhere, distribution and reimbursement wins supported smaller medtech names, and a cannabis merger plan kept Little Green Pharma in focus ahead of April’s vote.

Little Green Pharma Ltd (ASX: LGP) has proposed a full acquisition of Cannatrek Ltd via a scheme of arrangement, creating a vertically integrated medicinal cannabis group with pro forma FY26 revenues exceeding AUD 100 million. The scheme, supported by an independent expert, offers liquidity and strategic growth opportunities amid regulatory and market risks.

Two capital raisings and one brutal reset set the tone, even as several companies posted clean growth or strong clinical updates. Radiopharmaceuticals kept delivering good news, but investors still punished supply-chain and cash needs fast.

Little Green Pharma has entered a $7.8 million sale and leaseback agreement for its Western Australia production site, aiming to fuel growth in Australia and Europe while maintaining operational control.

A single exploration name blew the doors off the leaderboard, while two well-known uranium plays and a Nevada explorer sank hard. Behind the noise: deals got closer to completion, big raisings reset prices, and several “good news” gaps didn’t survive the week.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

Little Green Pharma Ltd is set to acquire Cannatrek Ltd in a transformative merger that will create one of the largest vertically integrated medicinal cannabis companies globally, with pro-forma FY25 revenue exceeding AUD 112 million.